Product Images Divalproex Sodium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Divalproex Sodium NDC 70518-1897 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Divalproex Sodium 500mg 70518 1897 01
Divalproex Sodium is a medication in the form of Extended-Release 500mg tablets. The package quantity is 100 HD2. The medication is meant for “RX ONLY”. The NDC code for the medication is 70518-1897-01. LOT #: and expiry date fields are left blank. The medication has been sourced from NDC 65862-0595-01 and manufactured by Aurcbindo Pharma, Dayton, NJ 08810. The package has a direction for use enclosed. It should be stored at a temperature range between 20-26°C (63-77°F), with excursions allowed to 15-30°C (59-86°F) [See USP]. The medication has been repackaged by Remedy Repack.*
Divalproex Sodium 500mg 70518 1897 02
Divalproex sodium is a medication available in tablet form with 500mg extended release formula. The package contains 1 HD2 tablet, and it is an RX only medication. The NDC number is 70518-1897-02, and the MFG is Aurcbindo Pharma located in Dayton, NJ. The package insert should be referred to for dosage information. The medication should be stored between 20-26°C, and should be kept out of reach of children. The medication is repackaged by RemedyRepack Inc. in Indiana.*
Remedy_Label - Remedy Label
Divalproex Sodium is an extended-release tablet of 500 mg. It comes in a quantity of 30 HD2 and needs a prescription to purchase. The package contains directions for use, and it's important to keep the medicine out of reach of children. Store it at 20-26°C (63-77°F), and it is permissible to keep it at 15-30°C (59-86°F) as per USP. The medicine is repackaged by RemedyRepack Inc., Indiana, PA 15701, 724.466.8762. The Lot number, expiration date, and source NDC are not available in the text.*
Figure 1 - divalproex fig1
The text describes a graph, labeled as Figure 1, that compares the reduction in CPS rate of patients taking delayed-release tablets of Divalproex Sodium versus those taking a placebo. The graph shows the percentage of patients who have experienced an improvement, no change, or worsening in their condition. The text is not sufficient to provide further details.*
Figure 2 - divalproex fig2
The text describes a figure labeled "Figure 2" which shows the % reduction in CPS rate for high and low dose Divalproex Sodium Delayed-Release Tablets. It includes three categories: improvement, no change, and worsening. The figure shows that the high dose has a greater reduction in CPS rate compared to the low dose.*
figure-3 - divalproex fig3
This appears to be a list of numerical values and some text referring to a medication called Divalproex Sodium Extended-Release Tablets. There is no clear context or further information provided.*
Structure - divalproex str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.